Drug Profile


Alternative Names: Anti-macrophage migration inhibitory factor antibody - Shire; Anti-MIF monoclonal antibody - Shire; BAX-069; BAX-69

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokine PharmaSciences
  • Developer Baxalta; Shire
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Macrophage migration inhibitory factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Malignant ascites
  • Phase I Solid tumours
  • Discontinued Lupus nephritis

Most Recent Events

  • 02 Jun 2017 Baxalta terminates a phase II trial in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA, Spain (NCT02448810)
  • 07 Oct 2016 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Oct 2016 Baxalta terminates a phase-I/II clinical trial in Malignant ascites (Recurrent) in USA and Hungary (IV) (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top